Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. - Wikidata - wikimedia - TriplyDB

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

http://www.wikidata.org/entity/Q33344746

about

Mechanism of action of lenalidomide in hematological malignancies Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance Multiple myeloma Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma Thalidomide analogues as anticancer drugs Elotuzumab for the treatment of multiple myeloma Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective New investigational drugs with single-agent activity in multiple myeloma Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.Management of the adverse effects of lenalidomide in multiple myeloma.Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.Bortezomib: the evidence of its clinical impact in multiple myeloma.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials.Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.Phase I study of oral lenalidomide in patients with refractory metastatic cancer Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.

P2860

Q21198872-E44EF3E8-81BD-4EE2-8714-86D1D04E8A65 Q21285161-249C4BC3-7059-4FED-B286-7EBF92D522F5 Q24644883-BD84E7C3-C0BC-4A32-9554-5D390E369849 Q24655964-FF51A3D1-F56B-4A3A-A8E0-DFDB828FC83B Q24669763-22DE24A8-565B-41E4-9AE6-51483D55D576 Q24669938-26A69F64-05AC-451D-BAEC-648EC7BD4916 Q24670383-CDAE1E57-8ACA-4B80-8378-E2EA7D920F97 Q26740278-2780690C-AC04-4B8E-A09B-59D1C9A5E378 Q27024932-AC12A6BA-413E-4130-9946-EC46FB9BD5A8 Q27026478-95AF28E7-1878-4150-BB1A-C5B72319C1A3 Q28069789-06CBFDCB-00F8-43BB-A989-8854AFC99E9C Q28071551-18D61B49-608A-48E3-A48D-19D8159966CB Q28192646-C9370D33-4909-419F-AB4D-3B49D7BE40DC Q28213525-6BD9E2AA-9C91-4D1D-A8FB-EBC7A5B38CB4 Q33322921-A24558BC-1A8C-406C-AD31-BB23993178E4 Q33364235-5A4AB995-6E3C-4524-B32B-CB58A206FB70 Q33376181-EAF35425-B567-4310-B0E0-9429CCF52FBE Q33386405-C2E47D9D-0F01-41EF-978E-402C693B39E6 Q33389075-64587EB1-9E60-42F9-AE62-666B6183A102 Q33390873-A3AA61E6-34BF-49F7-9107-8C9BCD187E76 Q33392683-EA742111-DA51-4556-B309-845E552D5386 Q33394632-6C42127D-1595-4194-A7CE-D0090E0A2BCA Q33396036-7F9C835C-B837-4317-8746-DC2F8667893E Q33397302-2115F7E6-72AD-47C2-BEF7-332844F644D4 Q33399416-4560ECCA-0CF2-41AF-AC3A-6301014075DB Q33400724-A0A6268B-1B50-4562-8F8E-4D968A12C784 Q33403183-00DA195D-8F24-4C3E-9D72-4003508C0D54 Q33408494-7DD59E84-97D4-411E-AEA5-CEA1B2818AB1 Q33408772-AE58830A-BAD1-456F-B261-A7716EA011FF Q33416468-FF13F8F2-F368-473E-B6E8-DCB7D69251DA Q33420263-3FD10BCC-1B27-4D92-B106-C93413E9696D Q33421008-815CB504-741D-4F1A-9299-F1DFBEE7C97F Q33421680-0B782FB0-D4ED-4E5A-B6D8-2389527BF997 Q33433453-E6C6C366-3B16-4683-B7B7-BDFAFFF6575F Q33440533-71CEBE6E-674D-4CE7-8AEE-3D963191568C Q33600521-CA98104B-DB2A-433F-8742-0AE0B0B40DDB Q33680252-31D3225C-1206-43EC-AD2C-FC94D1C2C2AA Q33702365-18B0198D-3F2D-4FE9-BD4D-8C26A3D5C079 Q33710588-26E25FA4-07EF-45D5-ADE2-2A0721062C94 Q33846310-0F49349C-9363-4A8F-AF4B-29F8DF7756AD

P2860

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

http://www.wikidata.org/entity/Q33344746

description

2002 nî lūn-bûn

@nan

2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Immunomodulatory drug CC-5013 ...... ith relapsed multiple myeloma.

@ast

Immunomodulatory drug CC-5013 ...... ith relapsed multiple myeloma.

@en

type

label

Immunomodulatory drug CC-5013 ...... ith relapsed multiple myeloma.

@ast

Immunomodulatory drug CC-5013 ...... ith relapsed multiple myeloma.

@en

prefLabel

Immunomodulatory drug CC-5013 ...... ith relapsed multiple myeloma.

@ast

Immunomodulatory drug CC-5013 ...... ith relapsed multiple myeloma.

@en

P1433

Q33344746-66431D5A-2FF0-4B2A-A847-2E6B9E34DEDB

P1476

Q33344746-7CD4FCDB-FEFB-4C3A-9AC9-B10D268E1A04

P2093

Q33344746-0B990F86-C3BA-4465-9AB9-3789E9D2CBC0

Q33344746-0BDB529B-9233-48AB-8617-E4E54CD0747B

Q33344746-14594466-7159-4F7A-BBAD-7D7E143294C8

Q33344746-324B24A8-8184-44BB-B140-E54F26143987

Q33344746-3F0B7D9A-C4D0-4CA7-9A16-31EA52D841B3

Q33344746-57F772EE-A010-4F59-8A53-18970E85CC73

Q33344746-5AE5F95F-20C8-4E21-9B92-C557EF892C24

Q33344746-7514FC04-19C1-45F2-9318-E8161D2C8DE0

Q33344746-75E6E74E-8DAF-4FCD-A25B-914D9F246748

Q33344746-7A5BC0D3-5E55-4AE7-86DB-3C5A964A6264

P304

Q33344746-8765F4B6-B936-4F91-994B-4D987E13DF2A

P31

Q33344746-0794BC9A-4505-4049-B671-CB5811CB4FD5

P356

Q33344746-8B6531B7-1B49-4BED-A7EC-63D0BEC2A0AF

P407

Q33344746-5288D07F-BF64-4233-8C59-355D437C61D6

P433

Q33344746-31BBB102-22A1-4D44-97F4-EFABD2ED4379

P478

Q33344746-61458B9C-F163-4FBB-B2D6-8EC18B236251

P50

Q33344746-085B637D-F613-4BA9-9F2E-1B7861034A8B

Q33344746-C35866A8-BCFF-4765-B539-6CB7F0B64DC8

P577

Q33344746-2409CF7C-4CEB-4D7D-8EC3-E301CC1583AA

P5875

Q33344746-0BC6BCEF-6C5E-446F-8316-24313D330882

P698

Q33344746-FCB0F2E5-7C74-4FF5-9076-A9EB44A7DDBB

P921

Q33344746-C2271838-EBA2-40CE-8496-90F4A6E41FA1

P356

BLOOD-2002-03-0996

P1433

P1476

Immunomodulatory drug CC-5013 ...... ith relapsed multiple myeloma.

@en

P2093

Andrea Freeman

http://www.w3.org/2001/XMLSchema#string

Constantine Mitsiades

http://www.w3.org/2001/XMLSchema#string

Deborah Doss

http://www.w3.org/2001/XMLSchema#string

Dharminder Chauhan

http://www.w3.org/2001/XMLSchema#string

Edie Weller

http://www.w3.org/2001/XMLSchema#string

Faith Davies

http://www.w3.org/2001/XMLSchema#string

Jerome Zeldis

http://www.w3.org/2001/XMLSchema#string

Joan J Ryoo

http://www.w3.org/2001/XMLSchema#string

Julie Mechlowicz

http://www.w3.org/2001/XMLSchema#string

Kathe Balinski

http://www.w3.org/2001/XMLSchema#string

P304

3063-3067

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2002-03-0996

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11077362

http://www.w3.org/2001/XMLSchema#string

P698

12384400

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance